Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAA817 +/- ARPI vs Standard of Care in PSMA-positive mCRPC
NCT06855277Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of actinium-225 PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Novartis. Primary endpoint: Radiographic Progression Free Survival up to 40.0 months. Started Jul 2025; status: recruiting.
02
Drugs
actinium-225 PSMA-617
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06855277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855277.